Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure

BMC Cardiovascular Disorders

Research Article

Thomas Kumler¹  Kasper Iversen²  Freja Stoltze Gaborit²  Morten Schou²  Finn Gustafsson³  György Sölétormos⁴  Jens P. Goetze⁵  Niels Tønder⁶  Helle Bosselmann⁷  Caroline Kistorp⁸ 

[1] Department of Cardiology, Herlev University Hospital, Herlev, Denmark;Department of Cardiology, Herlev University Hospital, Herlev, Denmark;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark;Department of Cardiology, Rigshospitalet, Copenhagen, Denmark;Department of Clinical Biochemistry, North Zealand University Hospital, Hillerod, Denmark;Department of Clinical Biochemistry, Rigshospitalet, Copenhagen, Denmark;Department of Internal Medicine KNEA, North Zealand University Hospital, Hillerod, Denmark;Department of Internal Medicine KNEA, North Zealand University Hospital, Hillerod, Denmark;Department of Cardiology, Rigshospitalet, Copenhagen, Denmark;Department of Internal Medicine, Endocrinology Unit, Herlev University Hospital, Herlev, Denmark;Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark;

关键词: Heart failure reduced ejection fraction;    Galectin 3;    Renal function;    Echocardiography;    Natriuretic peptides;   

DOI  :  10.1186/s12872-016-0290-7

 received in 2016-03-06, accepted in 2016-05-14,  发布年份 2016

来源: Springer

【 摘 要 】

BackgroundGalectin 3 (Gal-3) reflects cardiac fibrosis in heart failure HF, but has also been associated to renal fibrosis and impaired renal function. Previous research has suggested that Gal-3 could be a cardio-renal biomarker, but it has never been tested simultaneous in a single study whether Gal-3 reflects echocardiographic measures, neurohumoral activity and renal function.The aim of this study was to evaluate the relationship between plasma concentrations of Gal-3 and neurohumoral activity, myocardial and renal function in patients with HF, including advanced echocardiographic measures and 24-h urinary albumin excretion (albuminuria).MethodsWe prospectively enrolled 132 patients with reduced left ventricular ejection fraction (LVEF) referred to an outpatient HF clinic. The patients had a median age of 70 years (interquartile rage: 64–75), 26.5 % were female, median LVEF was 33 % (27–39 %) and 30 % were in NYHA class III-IV.ResultsPatients with plasma concentrations of Gal-3 above the median had significantly lower estimated glomerular filtration rate (eGFR) and this association remained significant in multivariate regression analysis (β: −0.010; 95 % CI −0.012–-0.008; P < 0.001), adjusted for age, gender, medical treatment. Plasma concentrations of Gal-3 were not associated with albuminuria (Beta: 0.008; 95 % CI:-0.028–0.045; P = 0.652). There were no association between plasma concentrations of Gal-3 and myocardial function or structure estimated by LVEF, LVmassIndex, LVIDd, E/é or LV global longitudinal strain (P > 0.05 for all). In multivariate analyses plasma concentrations of Gal-3 were significantly associated with the cardiac biomarkers: NT-proBNP (β: 0.047; 95 % CI: 0.008–0.086; P = 0.020), proANP (β: 0.137; 95 % CI: 0.067–0.207; P < 0.001), chromogranin A (β: 0.123; 95 % CI: 0.052–0.194; P < 0.001) and Copeptin (β: 0.080; 95 % CI: 0.000–0.160; P = 0.049). Multivariate analysis was adjusted for eGFR, age, gender and medical treatment.ConclusionsIncreased plasma concentrations of Gal-3 are associated with reduced eGFR and increased plasma concentrations of NT-proBNP, proANP, chromogranin A and Copeptin, but not with echocardiographic parameters reflecting myocardial function. These results suggest that Gal-3 reflects both increased neurohumoral activity and reduced eGFR, but not myocardial function in patients with systolic HF.

【 授权许可】

CC BY   
© The Author(s). 2016